ora™ is the industry’s first non-invasive endometrial receptivity test for identifying a patient’s optimal window of implantation (WOI).
Our microRNA-based test analyzes close to 300 microRNA (miRNA) biomarkers in the bloodstream that target over 1000 endometrial receptivity-related genes, alongside other physiological conditions for reliable, actionable results.
MIRA™ is our original microRNA-based endometrial receptivity test, increasing the IVF pregnancy rate to over 70% among patients with a history of implantation failure. The microRNA (miRNA) biomarkers in MIRA™ tolerate smaller-quantity and lower-quality tissue samples for a less invasive biopsy procedure to result in a <1% fail rate.
Inti’s pioneering miRNA-based endometrial receptivity test is used during the pre-implantation stage of in vitro fertilization (IVF) to enhance and personalize a patient’s treatment.
Inti Labs continues to progress the IVF landscape, empowering clinicians to make informed decisions that give their patients the best chance at a successful pregnancy.
We collaborate with clinics and distributors worldwide to offer insightful testing solutions that ensure the most personalized care for patients.
Our miRNA-based technology delivers more reliable and less invasive solutions that reduce the likelihood of patients needing to undergo multiple IVF cycles.